Anti-Digoxin Antibody Fab Fragments

Mechanism

Pharmacological Group and Molecular Target

Monovalent fragments of specific antibodies of ovine origin (Fab) against the cardiotonic drug digoxin.

Detailed Mechanism of Action

Digoxin inhibits the basolateral Na+/K+-ATPase pump in myocardial cells, which increases intracellular sodium and indirectly reduces calcium efflux through the NCX exchanger, increasing cardiac contractility. However, excess digoxin blocks the myocardial pump in a generalized way, causing a massive loss of intracellular potassium and triggering fatal atrial and ventricular arrhythmias due to increased automaticity and late afterdepolarizations.

Anti-digoxin Fab antibody fragments are produced by immunizing sheep with a digoxin-albumin conjugate. Subsequently, the purified IgG is subjected to enzymatic digestion with papain to cleave the Fc fraction, leaving only the monovalent antigen-binding fragments (Fab). These fragments travel through the plasma and bind with extremely high affinity (K_a ≈ 10¹⁰ M^-1) to circulating free digoxin molecules. This creates an intravascular concentration gradient that favors the passive passage of the drug fixed in the tissues and in the myocardial Na+/K+-ATPase pump into the plasma, deactivating its toxicity and allowing its rapid urinary clearance.

Pharmacokinetics

Pharmacokinetic and Toxicokinetic Profile

• Distribution: Limited volume of distribution (~0.4 L/kg). Diffuses into the interstitial space to capture tissue digoxin.
• Metabolism: Does not undergo metabolism through cytochrome pathways; It is slowly degraded by systemic tissue proteases.
• Excretion: Rapid renal in the form of Fab-digoxin immune complexes eliminated by glomerular filtration.
• Elimination half-life: Between 15 and 20 hours in patients with normal renal function. It is dramatically prolonged (up to 10 times longer) in patients with end-stage renal failure, which can cause dissociation of the immune complex and late recurrence of circulating free digoxin toxicity.

Indicators and dose

Specific Clinical Indications

• Acute or chronic digoxin toxicity associated with severe hemodynamic instability, lethal ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) or high-grade atrioventricular blocks refractory to atropine.
• Severe hyperkalemia secondary to digoxin toxicity (K⁺ > 5.0 mEq/L in acute poisoning, reflecting a massive blockage of the sodium-potassium pump).

Dosage Scheme and Infusion Protocols

Exact Stoichiometric Dose Calculation (40 mg Vials)

One vial of anti-digoxin Fab (40 mg) binds exactly 0.5 mg of systemic digoxin in the body.

1. If the total ingested dose of digoxin (mg) is known:

Number of Vials = (Dose ingested (mg) × 0.8)/(0.5 mg/vial)

2. If the steady-state serum digoxin concentration (ng/mL) is known:

Number of Vials = (Serum concentration (ng/mL) × Body weight (kg))/(100)

3. In case of acute poisoning with vital compromise and indeterminate data:Administer 10 vials (400 mg) as an IV infusion over 30 minutes in adults; 20 vials if massive ingestion is associated with imminent cardiac arrest.

Security

Contraindications and Precautions

• Known hypersensitivity to proteins of ovine (sheep) origin. In high-risk patients, the use of prior antihistamines should be considered.
• Caution: Rapid reversal of sodium-potassium pump blockade causes rapid entry of potassium into cells, which can cause severe rebound hypokalemia and destabilize treatment of pre-existing heart failure.